医疗旅游市场研究

由于本国医疗费用上涨、医疗行业全球化以及全球熟练医务人员的增加，医疗旅游已成为全球范围内一个不断发展的行业。新兴市场国家正优先发展该行业，以吸引医疗游客并促进医疗保健、生物技术和制药等先进服务行业的出口。

医疗旅游是指出国接受医疗护理的过程。尽管许多人认为医疗旅游是指人们从富裕国家前往发展中国家接受更便宜的医疗服务，但这一过程也适用于相反的情况，即来自欠发达国家的人前往富裕经济体接受本国不易提供的手术。

SIS 分析这种工作方式带来的所有潜在机会，以及潜在客户和供应商如何实现繁荣并提高治疗效果。

About the Medical Tourism Market

医疗旅游几乎遍布全球所有国家。例如，美国居民前往墨西哥、加拿大或中美洲和南美洲国家寻求更便宜的医疗服务，而欧洲人则前往欧盟以外或价格较低的国家之间旅行。

最受欢迎的目的地包括古巴、希腊、泰国、韩国和塞尔维亚，因为这些国家的医生和专家都是世界上最优秀的。

人们前往另一个国家接受医疗护理的最常见原因是：

1. 价格（许多人前往其他国家是因为他们自己买不起医疗保险，或者因为治疗费用远远超出他们的预算，所以我们可以得出结论，这是医疗旅游的主要原因）
2. 服务的合法性（一些国家的法律禁止某些医疗服务，例如堕胎或安乐死，但并非所有国家都禁止）
   文化差异（很多移民因为宗教信仰而希望在自己的原籍国得到待遇）
3. 访问实验程序
4. 获得更高质量的护理

人们决定去另一个国家进行的程序包括（但不限于）：生育治疗（例如代孕、体外受精和辅助生殖技术）、器官移植、整形手术、牙科护理和实验性癌症治疗。

客户旅程市场研究 can uncover numerous sources of competitive advantage in the Medical Tourism sector. Customers face numerous benefits and risks in medical tourism and the stakes can be high. Before patients decide to have their procedure done in a foreign country, they often conduct comprehensive in-person and online research to pick the right facility, treatment and medical provider for his or her needs. As these decisions can be outside their domestic medical establishments, the online research that patients conduct is important in their decision making. Furthermore, people who opt for medical tourism often exhaust all available medical treatment options in their home country so they can be a vulnerable group requiring information about benefits and risks. Market Research provides the insight for Medical Tourism providers to better serve potential patients.

医疗旅游最常见的并发症包括：

1. 疾病和感染风险——从手术并发症（伤口或供体感染）到远赴他国的传染病
2. 抗生素耐药性——这是一种相对罕见的风险，但每个医疗游客都需要意识到这一点
3. 沟通问题——只有注册机构才能为员工提供高级英语或患者母语知识，这对于适当的护理至关重要
4. 航空旅行——如果患者在手术后立即乘坐飞机，则面临较高的血栓风险或其他旅行风险，因此建议至少等待 10-14 天再回家

Medical 旅游市场研究: How Leading Operators Build Cross-Border Patient Pipelines

Medical tourism market research has shifted from descriptive country profiling to operational intelligence that informs corridor selection, payer partnerships, and clinical specialty positioning. The sophisticated buyers in this category, hospital networks, sovereign health funds, insurer-employer coalitions, and private equity-backed specialty groups, treat patient flow modeling the way airlines treat route economics.

The global cross-border patient market spans elective orthopedics, oncology second opinions, fertility, dental, cardiac, and bariatric procedures. Each travels along distinct corridors with distinct economics. Mexico-US dental and bariatric flows behave nothing like Gulf-to-Germany oncology referrals or China-to-Japan precision medicine cases. Treating them as a single market produces unusable forecasts.

Why Corridor-Level Medical Tourism Market Research Outperforms Country Reports

Country-level sizing obscures the unit of competition. Patients do not choose Thailand. They choose a specific Bangkok hospital with JCI accreditation, a named surgeon, an English-speaking concierge, and a payer arrangement that covers travel. Corridor analysis isolates origin-destination pairs and decomposes them into procedure mix, payer source, facilitator margin, and length-of-stay economics.

The leading operators model corridors the way logistics firms model lanes. Singapore-Indonesia cardiac. Turkey-UK hair restoration and dental. Costa Rica-US dental and orthopedics. Korea-China aesthetic surgery. India-East Africa oncology. Each corridor has a distinct conversion funnel from inquiry to deposit to arrival to follow-up, and the leakage points differ.

According to SIS International Research, the operators winning share in mature corridors invest heavily in pre-arrival clinical triage, often a structured remote consultation that qualifies the patient and pre-builds the care plan. This single step compresses on-site length of stay, reduces clinical surprises, and lifts deposit-to-arrival conversion materially above facilitator-led alternatives.

The Five Forces Reshaping Cross-Border Patient Flows

Five structural forces govern where the next decade of growth concentrates. Each is measurable and each rewards firms that build proprietary intelligence rather than rely on syndicated reports.

Payer integration. Self-funded US employers, UK NHS overflow contracting, and Gulf state-sponsored programs have moved from pilot to procurement. The buyer is no longer the patient. It is a benefits committee or a sovereign health authority running an RFP with bundled-price expectations and outcomes reporting requirements.

Accreditation as table stakes. JCI, Temos, and ISO 9001 certifications no longer differentiate. The differentiator is publishing risk-adjusted outcomes by surgeon and procedure, the standard set by Bumrungrad, Anadolu Medical Center, and Apollo Hospitals.

Facilitator disintermediation. Hospitals with mature international patient departments, Gleneagles, Asan Medical Center, Hospital Israelita Albert Einstein, are building direct payer relationships and bypassing traditional facilitators on high-margin cases.

Telemedicine pre-screening. Remote second opinions have become the top of the funnel. The hospital that captures the second opinion captures a disproportionate share of conversions.

Visa, currency, and geopolitical friction. Corridor economics shift quickly with visa policy and exchange rates. Turkey’s lira depreciation rebuilt its dental and aesthetic corridors within two years. Sanctions and travel restrictions can collapse a corridor in a quarter.

What Sophisticated Medical Tourism Market Research Actually Measures

Descriptive market sizing is the entry-level deliverable. The intelligence that informs capital allocation goes deeper.

Source: SIS International Research

The patient journey layer is where most market entry decks are weakest. Cross-border patients make decisions across an eight-to-fourteen-week window with multiple household stakeholders, and the conversion-killing moments are rarely clinical. They are visa anxiety, deposit refund policy ambiguity, and post-arrival communication gaps.

The SIS Approach to Medical Tourism Market Research

SIS International’s healthcare practice combines structured B2B expert interviews with international patient department directors, ethnographic research with returning patients, and competitive intelligence on hospital pricing, accreditation, and outcomes disclosure. A recent mixed-methodology engagement targeted 200 respondents across Brazil to map inbound and outbound patient flows for a Fortune 500 healthcare client evaluating Latin American corridor expansion.

The healthcare practice has fielded patient-side and provider-side studies across China, Mexico, the United States, Germany, Korea, Singapore, and Israel, including direct CEO-level interviews with overseas medical services agencies serving outbound Chinese patients. This dual-perspective design, capturing both the originating facilitator and the receiving hospital, surfaces the pricing and commission realities that single-sided studies miss.

SIS Corridor Viability Framework

Four dimensions determine whether a corridor merits investment.

• Volume durability. Is the patient flow tied to a structural cost or capacity gap, or to a temporary currency arbitrage?
• Payer concentration. Are the buyers individuals or institutional payers with renewable contracts?
• Clinical defensibility. Does the destination have outcomes data and surgeon depth that withstand a malpractice-conscious payer audit?
• Operational maturity. Are the international patient department, concierge, billing, and follow-up workflows institutionalized or improvised?

Corridors strong on all four, Singapore cardiac, Korea oncology, Turkey dental and orthopedics, sustain investment through currency cycles. Corridors weak on payer concentration or clinical defensibility tend to be margin-thin and reputation-fragile.

Where the Market Goes Next

Three shifts will define the next phase of corridor competition. First, employer-direct contracting will move from pilot programs at large self-funded US employers into mid-market benefits design, expanding addressable demand for centers of excellence in Mexico, Costa Rica, and Colombia. Second, fertility tourism will continue to outgrow other categories as regulatory arbitrage and donor availability concentrate volume in Spain, Greece, the Czech Republic, and parts of Latin America. Third, oncology second opinions delivered remotely will become the primary acquisition channel for high-acuity cross-border cases.

SIS International’s structured expert interviews with overseas medical services agencies indicate that destination preference among high-net-worth outbound patients is driven less by price and more by perceived clinical reputation, language infrastructure, and the agency’s own relationships with named physicians at receiving hospitals. The implication for hospitals is that physician-level brand investment outperforms institutional marketing in this segment.

Medical tourism market research that informs board-level decisions does not stop at market size. It quantifies corridor durability, payer concentration, clinical defensibility, and operational readiness, and it does so with primary evidence from both ends of the patient journey.

关于 SIS 国际

SIS 国际 提供定量、定性和战略研究。我们提供决策所需的数据、工具、战略、报告和见解。我们还进行访谈、调查、焦点小组和其他市场研究方法和途径。 联系我们 为您的下一个市场研究项目提供帮助。